{
    "nct_id": "NCT03661437",
    "official_title": "Light Therapy to Prevent Frailty in Older Men With Prostate Cancer on Hormonal Therapy: A Pilot RCT",
    "inclusion_criteria": "* Prostate cancer (PC) patients who are starting androgen deprivation therapy (ADT), abiraterone, or enzalutamide with plans to continue for at least six months with minimal evidence of disease burden in accordance with current standards of care.\n* A life expectancy of 6 months or longer.\n* All subjects must have the ability to understand and the willingness to sign a written or electronic informed consent.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 60 Years",
    "exclusion_criteria": "* Significant pre-existing frailty precluding completion of baseline assessments.\n* Other active malignancies\n* Previous use of radiation therapy within the year prior to consent.\n* Widely metastatic disease.\n* Confounding serious medical illnesses which causes frailty.\n* Severe sleep disorders.\n* Eye diseases which limit the ability of light to be processed.\n* Severe psychological impairment.\n* Current employment in night shift work.\n* Previous use of light therapy to alleviate fatigue or depressive symptoms.\n* Secondary cancer diagnosis within the past 5 years.\n* Plans to travel across meridians during treatment.\n* Uncontrolled illness including ongoing or active infection in disease status patients.",
    "miscellaneous_criteria": ""
}